Design: Phase 3 randomised trial (2:1) with crossover for MRD persistence
Population: 236 adults with newly diagnosed Ph-positive ALL (median age 55)
Primary outcome: Event-free survival
Effect: 24-month EFS 86% vs 67%; relapse 5% vs 13%; overall survival 90% vs 85%

GIMEMA ALL2820, a phase 3 trial published in NEJM on 15 October, randomised 236 adults with newly diagnosed Philadelphia-positive acute lymphoblastic leukaemia, median age 55, to ponatinib plus blinatumomab or imatinib plus chemotherapy. Patients in the control group with persistent or returning measurable residual disease could cross over.

At two years, event-free survival was 86% with the chemotherapy-free regimen and 67% with imatinib and chemotherapy. Complete haematological response at the end of induction was 94% against 79%, molecular response after consolidation 71% against 49%, and relapse 5% against 13%. Overall survival was 90% and 85%. Only 19% of the chemotherapy-free group had a transplant in first remission.

This supports a frontline approach that avoids intensive chemotherapy and, for many patients, transplant. It is particularly relevant for older adults, who tolerate chemotherapy poorly.

Ponatinib carries a known risk of arterial occlusive events, and both drugs are expensive. Access in India will be the main barrier.

Consider a chemotherapy-free ponatinib-blinatumomab approach for adults with newly diagnosed Ph-positive ALL where available.
Monitor measurable residual disease to guide decisions on transplant.
Assess cardiovascular risk before ponatinib, given its arterial occlusive risk.
Older adults may gain most from avoiding intensive chemotherapy.
Cost and availability of both drugs will limit access in many settings.

Why it matters

It moves Ph-positive ALL towards chemotherapy-free and often transplant-free treatment.

The statistics, in plain English

The 19-point gain in two-year event-free survival (86% vs 67%) is large and statistically clear. The overall survival difference (90% vs 85%) is smaller, partly because control patients could cross over to the experimental treatment.